Guselkumab is human monoclonal antibody to interleukin-23 and is used to treat severe psoriasis. Guselkumab is associated with a low rate of transient and asymptomatic serum enzyme elevations during therapy, but has not been linked to cases of idiosyncratic, clinically apparent liver injury.